Yann Hyvert

642 total citations
16 papers, 438 citations indexed

About

Yann Hyvert is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Yann Hyvert has authored 16 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 8 papers in Hematology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Yann Hyvert's work include Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Multiple Sclerosis Research Studies (6 papers). Yann Hyvert is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Multiple Sclerosis Research Studies (6 papers). Yann Hyvert collaborates with scholars based in United States, Germany and Switzerland. Yann Hyvert's co-authors include Mark S. Freedman, Alexey Boyко, Ernst W. Radü, Marc Lamarine, Ludwig Kappos, Thomas Plitz, Daniel D. Mikol, Hans‐Peter Hartung, Johan van Beek and Ulrich Freudensprung and has published in prestigious journals such as Neurology, The Lancet Neurology and Journal of Neuroimmunology.

In The Last Decade

Yann Hyvert

16 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yann Hyvert United States 7 287 213 113 93 69 16 438
Sebastian Torke Germany 10 295 1.0× 214 1.0× 76 0.7× 123 1.3× 89 1.3× 14 495
Laura Azzopardi United Kingdom 6 327 1.1× 218 1.0× 138 1.2× 121 1.3× 36 0.5× 9 479
Silke Häusser‐Kinzel Germany 15 409 1.4× 343 1.6× 103 0.9× 182 2.0× 39 0.6× 17 647
Tom Button United Kingdom 5 292 1.0× 138 0.6× 113 1.0× 91 1.0× 27 0.4× 6 377
Karolina Piasecka‐Stryczynska Poland 6 160 0.6× 101 0.5× 58 0.5× 74 0.8× 121 1.8× 15 303
Franziska Thaler Germany 10 196 0.7× 111 0.5× 70 0.6× 216 2.3× 22 0.3× 14 399
Eva Krasulová Czechia 5 196 0.7× 98 0.5× 64 0.6× 71 0.8× 20 0.3× 12 314
Mia Derstine United States 4 250 0.9× 246 1.2× 67 0.6× 97 1.0× 19 0.3× 13 411
Franz Felix Konen Germany 13 340 1.2× 91 0.4× 78 0.7× 181 1.9× 18 0.3× 42 509
Lena Bönig Germany 10 131 0.5× 60 0.3× 49 0.4× 117 1.3× 44 0.6× 13 349

Countries citing papers authored by Yann Hyvert

Since Specialization
Citations

This map shows the geographic impact of Yann Hyvert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yann Hyvert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yann Hyvert more than expected).

Fields of papers citing papers by Yann Hyvert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yann Hyvert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yann Hyvert. The network helps show where Yann Hyvert may publish in the future.

Co-authorship network of co-authors of Yann Hyvert

This figure shows the co-authorship network connecting the top 25 collaborators of Yann Hyvert. A scholar is included among the top collaborators of Yann Hyvert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yann Hyvert. Yann Hyvert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Montalbán, Xavier, Patrick Vermersch, Douglas L. Arnold, et al.. (2024). Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. The Lancet Neurology. 23(11). 1119–1132. 32 indexed citations
2.
3.
Arnold, Douglas L., et al.. (2024). Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis. Neurology. 102(5). e208058–e208058. 19 indexed citations
4.
Vermersch, Patrick, Douglas L. Arnold, Jerry S. Wolinsky, et al.. (2023). MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial. Multiple Sclerosis and Related Disorders. 71. 104360–104360. 2 indexed citations
5.
Montalbán, Xavier, Patrick Vermersch, Douglas L. Arnold, et al.. (2023). Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2). Multiple Sclerosis and Related Disorders. 80. 105328–105328. 2 indexed citations
6.
Bar‐Or, Amit, Anne H. Cross, Anthony L. Cunningham, et al.. (2023). Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor. Multiple Sclerosis Journal. 29(11-12). 1471–1481. 4 indexed citations
7.
Kühle, Jens, Ludwig Kappos, Xavier Montalbán, et al.. (2023). Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Decreases Neurofilament Light Chain Levels Over 2.5 Years of Treatment in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 71. 104357–104357. 2 indexed citations
8.
9.
10.
Freedman, Mark S., Jérôme Wojcik, Kristina Holmberg, et al.. (2021). Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION. Journal of Neuroimmunology. 360. 577715–577715. 5 indexed citations
11.
Freedman, Mark S., Patricia K. Coyle, Giancarlo Comi, et al.. (2021). Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis Journal - Experimental Translational and Clinical. 7(1). 2456410820–2456410820. 5 indexed citations
12.
Piasecka‐Stryczynska, Karolina, Konrad Rejdak, Martin C. Dyroff, et al.. (2021). Concentration of evobrutinib, a BTK inhibitor, in cerebrospinal fluid during treatment of patients with relapsing multiple sclerosis in a phase 2 study. Multiple Sclerosis and Related Disorders. 51. 103001–103001. 15 indexed citations
13.
Cree, Bruce, James D. Bowen, Hans‐Peter Hartung, et al.. (2020). Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis and Related Disorders. 49. 102695–102695. 8 indexed citations
14.
Stüve, Olaf, Thomas Leist, Gavin Giovannoni, et al.. (2019). Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Therapeutic Advances in Neurological Disorders. 12. 1278076554–1278076554. 79 indexed citations
15.
16.
Kappos, Ludwig, Hans‐Peter Hartung, Mark S. Freedman, et al.. (2014). Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Neurology. 13(4). 353–363. 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sebastian Torke Breakdown of academic impact, for papers by Laura Azzopardi Breakdown of academic impact, for papers by Silke Häusser‐Kinzel Breakdown of academic impact, for papers by Tom Button Breakdown of academic impact, for papers by Karolina Piasecka‐Stryczynska Breakdown of academic impact, for papers by Franziska Thaler Breakdown of academic impact, for papers by Eva Krasulová Breakdown of academic impact, for papers by Mia Derstine Breakdown of academic impact, for papers by Franz Felix Konen Breakdown of academic impact, for papers by Lena Bönig
Rankless by CCL
2026